News / Taiwan / economic_daily
JingTian Biotech Hits Record August Revenue, Partners with Bono Kangyuan for China Expansion
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-09-10
6917
JingTian Biotech reported record-breaking August revenue and signed an MOU with Bono Kangyuan to accelerate the development of topical drugs in China.
What Happened
Record Revenue: JingTian Biotech posted August revenue of NT$1.62 million, a 34.49% year-over-year increase, marking a new high since its listing on the Emerging Stock Board. The growth was driven by licensing income and strong sales of its core generic drugs.
Strategic Partnership: The company has signed an MOU with Bono Kangyuan to penetrate the Chinese market for topical pharmaceutical preparations. This partnership combines JingTian's R&D capabilities with Bono Kangyuan's local regulatory and distribution expertise.
Operational Synergy: The collaboration aims to shorten the time-to-market for new products and mitigate regulatory risks in China. Bono Kangyuan's background in high-end inhalation drug development and CDMO services will be instrumental in this expansion.
Future Outlook: With key new drugs nearing commercialization and generic drug sales growing, JingTian remains optimistic about its performance over the next two years. The company plans to continue expanding its niche product portfolio to maximize long-term value.